Table 2. Overview of EBI study characteristics (N = 225; n = 118) [28–145].
| Theme | Prioritised EBI | EBI, N (%) | Distribution of EBIs (N = 225) | ||||
|---|---|---|---|---|---|---|---|
| Country, N | Study Design, N | Implementation Outcome† | Theoretical Framework | Effectiveness Outcome† | |||
| Enabling high accessibility to HIV care services | Regular HIV testing for at-risk groups | 11 (5) | Australia: 3 Canada: 1 Spain: 1 USA: 6 |
RCT: 1 Observational study: 3 Hybrid study: 6 Qualitative study: 1 |
8 | 0 | 4 |
| Rapid access to testing services | 66 (29) | Australia: 13 Canada: 5 France: 8 Italy: 1 Spain: 3 UK: 5 USA: 31 |
RCT: 5 Observational study: 3 Hybrid study: 36 Qualitative study: 18 Quantitative study: 4 |
63 | 2 | 16 | |
| Rapid ART intervention | 2 (1) | USA: 2 | Observational study: 2 | 0 | 0 | 2 | |
| One-stop-shop model | 2 (1) | USA: 2 | Observational study: 2 | 0 | 0 | 2 | |
| Emergency advice service | 0 (0) | 0 | 0 | 0 | 0 | 0 | |
| Fostering an open and transparent environment | Access to mental health services | 7 (3) | USA: 7 | RCT: 4 Observational study: 1 Hybrid study: 1 Qualitative study: 1 |
3 | 2 | 6 |
| Creating an optimal care team model | Role of the pharmacist | 8 (4) | Australia: 2 Canada: 1 Spain: 1 USA: 4 |
RCT: 1 Observational study: 1 Hybrid study: 2 Qualitative study: 4 |
7 | 0 | 1 |
| Role of the care navigators | 63 (28) | Australia: 3 Canada: 3 France: 2 UK: 2 USA: 53 |
RCT: 4 Observational study: 3 Hybrid study: 23 Qualitative study: 12 Quantitative study: 21 |
56 | 5 | 19 | |
| Developing a personalized care management model | Individualised plan of care | 25 (11) | Canada: 1 USA: 24 |
RCT: 3 Hybrid study: 10 Quantitative study: 12 |
21 | 1 | 9 |
| Tracking and enabling retention in care | Structured follow-up | 35 (16) | Canada: 1 UK: 1 USA: 33 |
RCT: 4 Observational study: 8 Hybrid study: 13 Qualitative study: 3 Quantitative study: 7 |
21 | 3 | 19 |
| Proactive management of co-infections and co-morbidities | Diagnosis and management of co-infections | 2 (1) | Canada: 1 USA: 1 |
Observational study: 1 Quantitative study: 1 |
1 | 0 | 1 |
| Diagnosis and management of co-morbidities | 4 (2) | USA: 4 | Observational study: 1 Hybrid study: 3 |
3 | 0 | 2 | |
| Total | 225 (100) | 183 | 13 | 81 | |||
ART, antiretroviral therapy; EBI, evidence-based intervention; HIV, human immunodeficiency virus; N, number of EBIs identified.
N represents the total number of EBIs included in this review. n represents the number of publications in which these EBIs are evaluated. For study and intervention characteristics, refer to S2 Table.
†The sum of EBIs evaluated on implementation and EBIs evaluated on effectiveness do not add up to the total number of EBIs in each category as an EBI was counted in a category if it was at least assessed on any one outcome (i.e., implementation or effectiveness). The categories are not mutually exclusive.